Malaria: an intra-erythrocytic neoplasm?
Drug resistance is a serious problem in malaria, and prospects for new drugs are not optimistic. In 1963, the US Army began a huge programme to develop new antimalarials; they screened over 235 000 compounds, but very few were sufficiently active and safe for use in humans. Part of the problem is that not enough is known about the biochemical properties of malaria parasites, especially the metabolic differences between them and their host cells which could offer targets for specific chemotherapy. An important characteristic of malaria infection is the rapid growth of the parasite population, and changes in host metabolism that result from this. A similar effect occurs in many cancers. In this article, Ya Zhang argues that malaria parasites also have metabolic similarities with tumour cells, and suggests that careful comparison of these two could provide insight for new drug development.